- Home
- ACRS vs GLSI Comparison
ACRS vs GLSI Comparison
Compare ACRS & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- GLSI
- Stock Information
- Founded
- ACRS 2012
- GLSI 2006
- Country
- ACRS United States
- GLSI United States
- Employees
- ACRS N/A
- GLSI N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- ACRS Health Care
- GLSI Health Care
- Exchange
- ACRS Nasdaq
- GLSI Nasdaq
- Market Cap
- ACRS 165.7M
- GLSI 134.6M
- IPO Year
- ACRS 2015
- GLSI 2020
- Fundamental
- Price
- ACRS $1.53
- GLSI $11.09
- Analyst Decision
- ACRS Strong Buy
- GLSI Strong Buy
- Analyst Count
- ACRS 9
- GLSI 1
- Target Price
- ACRS $9.25
- GLSI $39.00
- AVG Volume (30 Days)
- ACRS 1.4M
- GLSI 79.0K
- Earning Date
- ACRS 08-11-2025
- GLSI 08-13-2025
- Dividend Yield
- ACRS N/A
- GLSI N/A
- EPS Growth
- ACRS N/A
- GLSI N/A
- EPS
- ACRS N/A
- GLSI N/A
- Revenue
- ACRS $17,777,000.00
- GLSI N/A
- Revenue This Year
- ACRS N/A
- GLSI N/A
- Revenue Next Year
- ACRS $8.11
- GLSI N/A
- P/E Ratio
- ACRS N/A
- GLSI N/A
- Revenue Growth
- ACRS N/A
- GLSI N/A
- 52 Week Low
- ACRS $1.05
- GLSI $8.06
- 52 Week High
- ACRS $5.17
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- ACRS 47.05
- GLSI 53.88
- Support Level
- ACRS $1.46
- GLSI $11.16
- Resistance Level
- ACRS $1.86
- GLSI $11.73
- Average True Range (ATR)
- ACRS 0.12
- GLSI 0.74
- MACD
- ACRS -0.02
- GLSI -0.08
- Stochastic Oscillator
- ACRS 17.54
- GLSI 42.91
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.